USD 19.32
↓ -1.53 (-7.34%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| HIMS | -7.3 | -22.1 | -10.4 | 24.0 | 32.6 | 158.6 | 137.9 | 95.2 | 97.1 | 97.1 |
| S&P 500 | -1.3 | -2.3 | 0.5 | 5.7 | 10.7 | 30.1 | 25.2 | 88.0 | 187.6 | 33142.5 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | HIMS |
| name | Hims & Hers Health, Inc. |
| price | 19.32 |
| changes percentage | -7.34 |
| change | -1.53 |
| day low | 19.15 |
| day high | 21.38 |
| year high | 30.44 |
| year low | 7.40 |
| market cap | 4059151320 |
| price avg 50 | 19.64 |
| price avg 200 | 17.02 |
| exchange | NYSE |
| volume | 31872464 |
| avg volume | 12243259 |
| open | 21.34 |
| previous close | 20.85 |
| eps | 0.33 |
| pe | 58.55 |
| earnings announcement | 2025-02-24T05:00:00.000+0000 |
| shares outstanding | 210101000 |
| timestamp | 2024-11-15 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001773751 | |||
| revenue | 872000000 | 526916000 | 65.49 |
| gross profit | 714949000 | 408722000 | 74.92 |
| gross profit ratio | 0.82 | 0.78 | 5.70 |
| research and development expenses | 48227000 | 29237000 | 64.95 |
| operating expenses | 744402000 | 477419000 | 55.92 |
| interest income | 0 | 2610000 | -100.00 |
| interest expense | 0 | 0 | NaN |
| ebitda | -19938000 | -61223000 | 67.43 |
| ebitdaratio | -0.02 | -0.12 | 80.32 |
| operating income | -29453000 | -68697000 | 57.13 |
| operating income ratio | -0.03 | -0.13 | 74.09 |
| net income | -23546000 | -65678000 | 64.15 |
| net income ratio | -0.03 | -0.12 | 78.34 |
| eps | -0.11 | -0.32 | 65.62 |
Revenue Growth: revenue increased to 872 million in 2023 from 527 million in 2022 representing a change of 65.49%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 715 million in 2023 from 409 million in 2022 representing a change of 74.92%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 48 million in 2023 from 29 million in 2022 representing a change of 64.95%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Earnings per Share (EPS): EPS increased to -0.11 in 2023 from -0.11 in 2022 representing a change of 65.62%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 744 million in 2023 from 477 million in 2022 representing a change of 55.92%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -20 million in 2023 from -61 million in 2022 representing a change of 67.43%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -29 million in 2023 from -69 million in 2022 representing a change of 57.13%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -24 million in 2023 from -66 million in 2022 representing a change of 64.15%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001773751 | |||
| revenue | 401556000 | 315648000 | 27.22 |
| gross profit | 317886000 | 215160000 | 47.74 |
| gross profit ratio | 0.79 | 0.68 | 16.14 |
| research and development expenses | 21092000 | 18654000 | 13.07 |
| operating expenses | 295512000 | 203501000 | 45.21 |
| interest income | 0 | 0 | NaN |
| interest expense | 0 | 0 | NaN |
| ebitda | 22374000 | 14673000 | 52.48 |
| ebitdaratio | 0.06 | 0.05 | 14.94 |
| operating income | 22374000 | 11659000 | 91.90 |
| operating income ratio | 0.06 | 0.04 | 50.85 |
| net income | 75588000 | 13297000 | 468.46 |
| net income ratio | 0.19 | 0.04 | 346.84 |
| eps | 0.35 | 0.06 | 464.52 |
Revenue Growth: revenue increased to 402 million in 2024Q3 from 316 million in 2024Q2 representing a change of 27.22%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 318 million in 2024Q3 from 215 million in 2024Q2 representing a change of 47.74%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 21 million in 2024Q3 from 19 million in 2024Q2 representing a change of 13.07%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 22 million in 2024Q3 from 15 million in 2024Q2 representing a change of 52.48%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 22 million in 2024Q3 from 12 million in 2024Q2 representing a change of 91.9%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to 76 million in 2024Q3 from 13 million in 2024Q2 representing a change of 468.46%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 0.35 in 2024Q3 from 0.35 in 2024Q2 representing a change of 464.52%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 296 million in 2024Q3 from 204 million in 2024Q2 representing a change of 45.21%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001773751 | |||
| total assets | 441186000 | 366341000 | 20.43 |
| total liabilities | 97157000 | 54600000 | 77.94 |
| total equity | 344029000 | 311741000 | 10.36 |
| cash and cash equivalents | 96663000 | 46772000 | 106.67 |
| short term investments | 124318000 | 132853000 | -6.42 |
| long term investments | 0 | 856000 | -100.00 |
| total current assets | 265053000 | 216595000 | 22.37 |
| total non current assets | 176133000 | 149746000 | 17.62 |
| total current liabilities | 88468000 | 47941000 | 84.54 |
| total non current liabilities | 8689000 | 6659000 | 30.49 |
| common stock | 21000 | 21000 | 0.00 |
| retained earnings | -368175000 | -344629000 | -6.83 |
| total debt | 9948000 | 5307000 | 87.45 |
Total Assets: Total Assets increased to 441 million in 2023 from 366 million in 2022 representing a change of 20.43%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 344 million in 2023 from 312 million in 2022 representing a change of 10.36%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 97 million in 2023 from 47 million in 2022 representing a change of 106.67%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 265 million in 2023 from 217 million in 2022 representing a change of 22.37%. This indicates a better liquidity position.
Total Liabilities: Total Liabilities increased to 97 million in 2023 from 55 million in 2022 representing a change of 77.94%. This indicates an increase in overall liabilities.
Short Term Investments: Short Term Investments decreased to 124 million in 2023 from 133 million in 2022 representing a change of -6.42%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 88 million in 2023 from 48 million in 2022 representing a change of 84.54%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -368 million in 2023 from -345 million in 2022 representing a change of -6.83%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 10 million in 2023 from 5 million in 2022 representing a change of 87.45%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001773751 | |||
| total assets | 602261000 | 480500000 | 25.34 |
| total liabilities | 162210000 | 118534000 | 36.85 |
| total equity | 440051000 | 361966000 | 21.57 |
| cash and cash equivalents | 165518000 | 129294999 | 28.02 |
| short term investments | 88553000 | 97997000 | -9.64 |
| long term investments | 0 | 856000 | -100.00 |
| total current assets | 326375000 | 290918000 | 12.19 |
| total non current assets | 275886000 | 189582000 | 45.52 |
| total current liabilities | 152645000 | 108671000 | 40.47 |
| total non current liabilities | 9565000 | 9863000 | -3.02 |
| common stock | 22000 | 22000 | 0.00 |
| retained earnings | -268162000 | -343750000 | 21.99 |
| total debt | 11358000 | 11475000 | -1.02 |
Total Assets: Total Assets increased to 602 million in 2024Q3 from 480 million in 2024Q2 representing a change of 25.34%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 440 million in 2024Q3 from 362 million in 2024Q2 representing a change of 21.57%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 166 million in 2024Q3 from 129 million in 2024Q2 representing a change of 28.02%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 326 million in 2024Q3 from 291 million in 2024Q2 representing a change of 12.19%. This indicates a better liquidity position.
Retained Earnings: Retained Earnings increased to -268 million in 2024Q3 from -344 million in 2024Q2 representing a change of 21.99%. This indicates an accumulated profits.
Total Debt: Total Debt decreased to 11 million in 2024Q3 from 11 million in 2024Q2 representing a change of -1.02%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 162 million in 2024Q3 from 119 million in 2024Q2 representing a change of 36.85%. This indicates an increase in overall liabilities.
Short Term Investments: Short Term Investments decreased to 89 million in 2024Q3 from 98 million in 2024Q2 representing a change of -9.64%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 153 million in 2024Q3 from 109 million in 2024Q2 representing a change of 40.47%. This indicates a higher short-term debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001773751 | |||
| net change in cash | 49891000 | -25012000 | 299.47 |
| operating cash flow | 73483000 | -26531000 | 376.97 |
| free cash flow | 46991000 | -33778000 | 239.12 |
| capital expenditure | -26492000 | -7247000 | -265.56 |
| depreciation and amortization | 9515000 | 7474000 | 27.31 |
| deferred income tax | -13000 | -594000 | 97.81 |
| stock based compensation | 66080000 | 42817000 | 54.33 |
| accounts payables | 7324000 | 12723000 | -42.43 |
| inventory | -902000 | -8004000 | 88.73 |
| acquisitions net | 0 | -459000 | 100.00 |
| investments in property plant and equipment | -17220000 | -7247000 | -137.62 |
| net cash used for investing activites | -12106000 | 34699000 | -134.89 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 0 | 2246000 | -100.00 |
| common stock repurchased | -1999000 | -3901000 | 48.76 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -11475000 | -33127000 | 65.36 |
| cash at end of period | 97519000 | 47628000 | 104.75 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 47628000 | 72640000 | -34.43 |
Net Change in Cash: Net Change in Cash increased to 50 million in 2023 from -25 million in 2022 representing a change of 299.47%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 73 million in 2023 from -27 million in 2022 representing a change of 376.97%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 47 million in 2023 from -34 million in 2022 representing a change of 239.12%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -26 million in 2023 from -7 million in 2022 representing a change of -265.56%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Payables: The absolute value of Accounts Payables decreased to 7 million in 2023 from 13 million in 2022 representing a change of -42.43%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Deferred Income Tax: Deferred Income Tax increased to 0 million in 2023 from -1 million in 2022 representing a change of 97.81%. This indicates that the company's tax liability for future periods has increased.
Stock-Based Compensation: Stock-Based Compensation increased to 66 million in 2023 from 43 million in 2022 representing a change of 54.33%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001773751 | |||
| operating cash flow | 85267000 | 53594000 | 59.10 |
| free cash flow | 88116000 | 47568000 | 85.24 |
| capital expenditure | 2849000 | -6026000 | 147.28 |
| depreciation and amortization | 4383000 | 3643000 | 20.31 |
| deferred income tax | -54340000 | 0 | NaN |
| stock based compensation | 24899000 | 24042000 | 3.56 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | 18896000 | 12554000 | 50.52 |
| inventory | -8171000 | -10762000 | 24.08 |
| acquisitions net | -15399000 | 0 | NaN |
| investments in property plant and equipment | 2849000 | -6026000 | 147.28 |
| net cash used for investing activites | -10414000 | -4470000 | -132.98 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | -30038000 | -19932000 | -50.70 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -38820000 | -25065000 | -54.88 |
| net change in cash | 37079001 | 24057999 | 54.12 |
| cash at end of period | 166374000 | 129294999 | 28.68 |
| cash at beginning of period | 129294999 | 105237000 | 22.86 |
Net Change in Cash: Net Change in Cash increased to 37 million in 2024Q3 from 24 million in 2024Q2 representing a change of 54.12%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 85 million in 2024Q3 from 54 million in 2024Q2 representing a change of 59.1%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 88 million in 2024Q3 from 48 million in 2024Q2 representing a change of 85.24%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 3 million in 2024Q3 from -6 million in 2024Q2 representing a change of 147.28%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 25 million in 2024Q3 from 24 million in 2024Q2 representing a change of 3.56%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 19 million in 2024Q3 from 13 million in 2024Q2 representing a change of 50.52%. This indicates that the company has increased its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 4.17 | 2.58 | 61.67 |
| net income per share | -0.11 | -0.32 | 64.98 |
| operating cash flow per share | 0.35 | -0.13 | 370.58 |
| free cash flow per share | 0.22 | -0.17 | 235.91 |
| cash per share | 1.06 | 0.88 | 20.19 |
| book value per share | 1.64 | 1.52 | 7.81 |
| tangible book value per share | 1.02 | 0.88 | 17.10 |
| shareholders equity per share | 1.64 | 1.52 | 7.81 |
| interest debt per share | 0.01 | 0.01 | -24.52 |
| market cap | 1863167936.8 | 1310948329.2 | 42.12 |
| enterprise value | 1776452936.8 | 1269483329.2 | 39.94 |
| pe ratio | -79.13 | -19.96 | -296.43 |
| price to sales ratio | 2.14 | 2.49 | -14.12 |
| pocfratio | 25.36 | -49.41 | 151.31 |
| pfcf ratio | 39.65 | -38.81 | 202.16 |
| pb ratio | 5.42 | 4.21 | 28.79 |
| ptb ratio | 5.42 | 4.21 | 28.79 |
| ev to sales | 2.04 | 2.41 | -15.44 |
| enterprise value over ebitda | -89.1 | -20.74 | -329.69 |
| ev to operating cash flow | 24.18 | -47.85 | 150.52 |
| ev to free cash flow | 37.8 | -37.58 | 200.59 |
| earnings yield | -0.01 | -0.05 | 74.78 |
| free cash flow yield | 0.03 | -0.03 | 197.88 |
| debt to equity | 0.0 | 0.01 | -29.99 |
| debt to assets | 0.0 | 0.0 | -35.85 |
| net debt to ebitda | 4.35 | 0.68 | 542.16 |
| current ratio | 3.0 | 4.52 | -33.69 |
| interest coverage | 0 | 0 | NaN |
| income quality | -3.12 | 0.4 | -872.57 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.15 | 0.19 | -20.07 |
| research and ddevelopement to revenue | 0.06 | 0.06 | -0.33 |
| intangibles to total assets | 0.29 | 0.36 | -19.01 |
| capex to operating cash flow | 0.36 | -0.27 | 231.98 |
| capex to revenue | 0.03 | 0.01 | 120.89 |
| capex to depreciation | 2.78 | 0.97 | 187.14 |
| stock based compensation to revenue | 0.08 | 0.08 | -6.74 |
| graham number | 2.04 | 3.32 | -38.55 |
| roic | -0.09 | -0.22 | 57.51 |
| return on tangible assets | -0.08 | -0.28 | 73.13 |
| graham net net | 0.67 | 0.68 | -1.53 |
| working capital | 176585000 | 168654000 | 4.70 |
| tangible asset value | 214574000 | 179019000 | 19.86 |
| net current asset value | 167896000 | 161995000 | 3.64 |
| invested capital | 351771000 | 306312000 | 14.84 |
| average receivables | 4468000 | 3404000 | 31.26 |
| average payables | 37716500 | 26001500 | 45.06 |
| average inventory | 22013000 | 17560000 | 25.36 |
| days sales outstanding | 2.39 | 2.24 | 6.69 |
| days payables outstanding | 100.1 | 99.94 | 0.16 |
| days of inventory on hand | 52.21 | 66.59 | -21.59 |
| receivables turnover | 152.85 | 163.08 | -6.27 |
| payables turnover | 3.65 | 3.65 | -0.16 |
| inventory turnover | 6.99 | 5.48 | 27.54 |
| roe | -0.07 | -0.21 | 67.51 |
| capex per share | 0.13 | 0.04 | 257.13 |
ROE: Return on Equity (ROE) increased to -0.07 on 2023-12-31 from -0.21 on 2022-12-31, representing a change of 67.51%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -79.13 on 2023-12-31 from -19.96 on 2022-12-31, representing a change of -296.43%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 3.00 on 2023-12-31 from 4.52 on 2022-12-31, representing a change of -33.69%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2023-12-31 from 0.01 on 2022-12-31, representing a change of -29.99%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| HIMS | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 1.85 | 1.47 | 26.04 |
| net income per share | 0.35 | 0.06 | 463.21 |
| operating cash flow per share | 0.39 | 0.25 | 57.63 |
| free cash flow per share | 0.41 | 0.22 | 83.53 |
| cash per share | 1.17 | 1.06 | 10.75 |
| book value per share | 2.03 | 1.69 | 20.45 |
| tangible book value per share | 1.3 | 1.09 | 19.64 |
| shareholders equity per share | 2.03 | 1.69 | 20.45 |
| interest debt per share | 0.01 | 0.01 | 8.72 |
| market cap | 3990087774.06 | 4597118352.54 | -13.20 |
| enterprise value | 3835927774.06 | 4479298353.54 | -14.36 |
| pe ratio | 13.2 | 86.43 | -84.73 |
| price to sales ratio | 9.94 | 14.56 | -31.77 |
| pocfratio | 46.8 | 85.78 | -45.45 |
| pfcf ratio | 45.28 | 96.64 | -53.14 |
| pb ratio | 9.07 | 12.7 | -28.61 |
| ptb ratio | 9.07 | 12.7 | -28.61 |
| ev to sales | 9.55 | 14.19 | -32.68 |
| enterprise value over ebitda | 171.45 | 305.27 | -43.84 |
| ev to operating cash flow | 44.99 | 83.58 | -46.17 |
| ev to free cash flow | 43.53 | 94.17 | -53.77 |
| earnings yield | 0.02 | 0.0 | 554.94 |
| free cash flow yield | 0.02 | 0.01 | 113.42 |
| debt to equity | 0.0 | 0.0 | -9.74 |
| debt to assets | 0.0 | 0.0 | -12.45 |
| net debt to ebitda | -6.89 | -8.03 | 14.19 |
| current ratio | 2.14 | 2.68 | -20.13 |
| interest coverage | 0 | 0 | NaN |
| income quality | 1.13 | 4.03 | -72.01 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.11 | 0.13 | -13.52 |
| research and ddevelopement to revenue | 0.05 | 0.06 | -11.12 |
| intangibles to total assets | 0.26 | 0.27 | -1.81 |
| capex to operating cash flow | 0.03 | 0.11 | -70.28 |
| capex to revenue | 0.01 | 0.02 | -62.84 |
| capex to depreciation | 0.65 | 1.65 | -60.70 |
| stock based compensation to revenue | 0.06 | 0.08 | -18.59 |
| graham number | 3.99 | 1.53 | 160.46 |
| roic | 0.16 | 0.03 | 410.78 |
| return on tangible assets | 0.17 | 0.04 | 350.57 |
| graham net net | 0.55 | 0.62 | -10.87 |
| working capital | 173730000 | 182247000 | -4.67 |
| tangible asset value | 282505000 | 233952000 | 20.75 |
| net current asset value | 164165000 | 172384000 | -4.77 |
| invested capital | 394304000 | 370835000 | 6.33 |
| average receivables | 5062500 | 5978000 | -15.31 |
| average payables | 66271500 | 50509000 | 31.21 |
| average inventory | 44849000 | 35207000 | 27.39 |
| days sales outstanding | 1.03 | 1.58 | -35.23 |
| days payables outstanding | 81.15 | 51.14 | 58.69 |
| days of inventory on hand | 52.83 | 36.35 | 45.32 |
| receivables turnover | 87.79 | 56.86 | 54.39 |
| payables turnover | 1.11 | 1.76 | -36.98 |
| inventory turnover | 1.7 | 2.48 | -31.18 |
| roe | 0.17 | 0.04 | 367.59 |
| capex per share | 0.01 | 0.03 | -53.16 |
ROE: Return on Equity (ROE) increased to 0.17 on 2024-09-30 Q3 from 0.04 on 2024-06-30 Q2, representing a change of 367.59%. Suggesting the company has been generating high returns for its shareholders.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2024-09-30 Q3 from 0.00 on 2024-06-30 Q2, representing a change of -9.74%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to 13.20 on 2024-09-30 Q3 from 86.43 on 2024-06-30 Q2, representing a change of -84.73%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 2.14 on 2024-09-30 Q3 from 2.68 on 2024-06-30 Q2, representing a change of -20.13%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-16 10:30:00
Hims & Hers has given back recent gains, but don't overlook the company's massive growth.
Sentiment: Neutral
Publish Date: 2024-11-16 07:15:00
Should You Buy Hims & Hers Stock on the Dip?
Sentiment: Positive
Publish Date: 2024-11-16 04:40:15
Hims & Hers stands out from Teladoc by focusing on direct-to-consumer telehealth services, contrasting Teladoc's business-to-business model. This telehealth company provides personalized treatments to select conditions like weight loss, hair loss, and sexual health. A reverse DCF analysis suggests its current stock price is more than justified.
Sentiment: Positive
Publish Date: 2024-11-15 12:37:39
Hims & Hers Health, Inc.'s stock dropped over 25% over the last 2 days due to Amazon's entry into the hair loss and ED markets, but I believe investor pessimism is overblown. Despite Amazon's competition, Hims & Hers's focus on personalized solutions, which saw 175% YoY growth, provides a strong competitive moat. Even with conservative growth estimates, Hims & Hers has a 38% upside potential, maintaining my “buy” rating with a $27.5 price target.
Sentiment: Positive
Publish Date: 2024-11-15 08:10:53
Hims & Hers Health, a telehealth service for clients to access healthcare and prescriptions from home, is seeing its stock take a steep dive on Thursday, just after Amazon announced updates to a strikingly similar service for Prime members.
Sentiment: Neutral
Publish Date: 2024-11-14 14:40:00
Amazon is now offering upfront pricing for virtual care for ailments such as men's hair loss and ED.
Sentiment: Positive
Publish Date: 2024-11-14 11:18:41
Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing for telehealth visits.
Sentiment: Positive
Publish Date: 2024-11-14 10:26:27
Amazon announced Prime members can access new upfront pricing to treat five common conditions like erectile dysfunction and men's hair loss. The move places the company in competition with other direct-to-consumer marketplaces like Hims & Hers Health and Ro.
Sentiment: Positive
Publish Date: 2024-11-13 12:17:39
Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's Wegovy.
Sentiment: Positive
Publish Date: 2024-11-13 11:30:42
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Sentiment: Positive
Publish Date: 2024-11-12 11:35:38
Shopify's (SHOP) massive pop after earnings is just the latest flex of Consumer Discretionary's strength, according to Roxanna Islam. The sector has grown 20% year-to-date compared to Consumer Staples.
Sentiment: Negative
Publish Date: 2024-11-12 09:13:37
The healthcare company is on fire, and it's still cheap by many measures.
Sentiment: Positive
Publish Date: 2024-11-12 08:00:01
Every earnings season has its share of outperformers, companies that report blowout quarters and raise their forecasts. The market reacts quickly sending shares sharply higher.
Sentiment: Positive
Publish Date: 2024-11-11 10:05:36
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Sentiment: Positive
Publish Date: 2024-11-09 10:00:00
H&H's strong Q3 results signals a fundamental shift in the healthcare industry. GLP-1 drugs are certainly a growth catalyst for H&H but it is just a tiny component of the overall investment thesis. H&H investments in AI will drive massive efficiency gains while delivering immense value for providers and patients.
Sentiment: Positive
Publish Date: 2024-11-08 15:52:53
Hims & Hers is a rapidly emerging player in telehealth and wellness, catering to millennials and Gen Z. The company reported a 77% year-over-year revenue growth, with a subscriber base of 2 million. Hims & Hers' strategic marketing investments have led to positive net income, with potential for further growth and profitability.
Sentiment: Positive
Publish Date: 2024-11-08 13:21:14
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Sentiment: Positive
Publish Date: 2024-11-08 04:20:00
Hims & Hers strong performance involves much more than just GLP-1 drugs.
Sentiment: Positive
Publish Date: 2024-11-06 12:36:55
The company expects to enjoy many GLP-1 tailwinds in 2025.
Sentiment: Positive
Publish Date: 2024-11-06 08:21:30
Most investors would look at an earnings announcement as a past event, connecting the current price action in the stock and reacting to the results as something that cannot be taken advantage of, thinking that it is now too late to get into action. This might be the case for shares of Hims & Hers Health Inc. NYSE: HIMS, as the stock is now rallying by over 6% the morning after the company reported its quarterly earnings.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
